扶桑薬品工業の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/12/02 | 2,598 | 2,609 | 2,571 | 2,595 | -5 | -0.2% | 11,000 |
| 2024/11/29 | 2,635 | 2,639 | 2,597 | 2,600 | -34 | -1.3% | 8,300 |
| 2024/11/28 | 2,594 | 2,634 | 2,594 | 2,634 | +38 | +1.5% | 7,600 |
| 2024/11/27 | 2,635 | 2,645 | 2,593 | 2,596 | -20 | -0.8% | 10,400 |
| 2024/11/26 | 2,611 | 2,644 | 2,602 | 2,616 | -4 | -0.2% | 7,900 |
| 2024/11/25 | 2,644 | 2,673 | 2,620 | 2,620 | -40 | -1.5% | 11,500 |
| 2024/11/22 | 2,595 | 2,662 | 2,595 | 2,660 | +53 | +2% | 12,000 |
| 2024/11/21 | 2,613 | 2,637 | 2,601 | 2,607 | -6 | -0.2% | 8,000 |
| 2024/11/20 | 2,685 | 2,688 | 2,613 | 2,613 | -85 | -3.2% | 12,200 |
| 2024/11/19 | 2,658 | 2,700 | 2,658 | 2,698 | +40 | +1.5% | 12,000 |
| 2024/11/18 | 2,624 | 2,658 | 2,611 | 2,658 | +7 | +0.3% | 14,400 |
| 2024/11/15 | 2,650 | 2,666 | 2,602 | 2,651 | +18 | +0.7% | 22,600 |
| 2024/11/14 | 2,672 | 2,709 | 2,633 | 2,633 | -29 | -1.1% | 17,300 |
| 2024/11/13 | 2,623 | 2,677 | 2,590 | 2,662 | +31 | +1.2% | 26,500 |
| 2024/11/12 | 2,700 | 2,735 | 2,630 | 2,631 | -21 | -0.8% | 51,800 |
| 2024/11/11 | 2,719 | 2,858 | 2,610 | 2,652 | -63 | -2.3% | 234,100 |
| 2024/11/08 | 2,711 | 2,719 | 2,667 | 2,715 | -5 | -0.2% | 18,800 |
| 2024/11/07 | 2,645 | 2,739 | 2,630 | 2,720 | +90 | +3.4% | 31,200 |
| 2024/11/06 | 2,650 | 2,689 | 2,609 | 2,630 | -69 | -2.6% | 28,800 |
| 2024/11/05 | 2,797 | 2,806 | 2,627 | 2,699 | +148 | +5.8% | 150,400 |
| 2024/11/01 | 2,547 | 2,565 | 2,536 | 2,551 | +3 | +0.1% | 9,100 |
| 2024/10/31 | 2,500 | 2,557 | 2,490 | 2,548 | +58 | +2.3% | 30,900 |
| 2024/10/30 | 2,473 | 2,490 | 2,458 | 2,490 | +36 | +1.5% | 83,600 |
| 2024/10/29 | 2,415 | 2,456 | 2,399 | 2,454 | +39 | +1.6% | 14,900 |
| 2024/10/28 | 2,366 | 2,415 | 2,366 | 2,415 | +66 | +2.8% | 13,500 |
| 2024/10/25 | 2,385 | 2,385 | 2,336 | 2,349 | -11 | -0.5% | 9,700 |
| 2024/10/24 | 2,352 | 2,391 | 2,352 | 2,360 | -1 | ±0% | 12,400 |
| 2024/10/23 | 2,402 | 2,410 | 2,361 | 2,361 | -24 | -1% | 9,700 |
| 2024/10/22 | 2,443 | 2,448 | 2,385 | 2,385 | -56 | -2.3% | 18,300 |
| 2024/10/21 | 2,430 | 2,470 | 2,413 | 2,441 | +18 | +0.7% | 20,800 |
| 2024/10/18 | 2,386 | 2,430 | 2,386 | 2,423 | +51 | +2.2% | 15,500 |
| 2024/10/17 | 2,361 | 2,389 | 2,361 | 2,372 | +16 | +0.7% | 10,600 |
| 2024/10/16 | 2,352 | 2,384 | 2,326 | 2,356 | -5 | -0.2% | 13,300 |
| 2024/10/15 | 2,357 | 2,370 | 2,334 | 2,361 | +28 | +1.2% | 7,900 |
| 2024/10/11 | 2,335 | 2,365 | 2,312 | 2,333 | -2 | -0.1% | 15,900 |
| 2024/10/10 | 2,333 | 2,335 | 2,302 | 2,335 | +2 | +0.1% | 4,500 |
| 2024/10/09 | 2,334 | 2,334 | 2,305 | 2,333 | +8 | +0.3% | 7,700 |
| 2024/10/08 | 2,331 | 2,334 | 2,308 | 2,325 | -8 | -0.3% | 5,700 |
| 2024/10/07 | 2,342 | 2,342 | 2,316 | 2,333 | +17 | +0.7% | 9,200 |
| 2024/10/04 | 2,306 | 2,319 | 2,299 | 2,316 | +10 | +0.4% | 7,100 |
| 2024/10/03 | 2,334 | 2,339 | 2,289 | 2,306 | +40 | +1.8% | 9,900 |
| 2024/10/02 | 2,249 | 2,290 | 2,249 | 2,266 | -1 | ±0% | 10,200 |
| 2024/10/01 | 2,277 | 2,277 | 2,255 | 2,267 | +20 | +0.9% | 6,300 |
| 2024/09/30 | 2,230 | 2,260 | 2,230 | 2,247 | -13 | -0.6% | 10,100 |
| 2024/09/27 | 2,274 | 2,281 | 2,248 | 2,260 | -59 | -2.5% | 9,300 |
| 2024/09/26 | 2,298 | 2,319 | 2,270 | 2,319 | +31 | +1.4% | 28,300 |
| 2024/09/25 | 2,267 | 2,288 | 2,264 | 2,288 | +18 | +0.8% | 11,400 |
| 2024/09/24 | 2,250 | 2,282 | 2,238 | 2,270 | +32 | +1.4% | 12,900 |
| 2024/09/20 | 2,220 | 2,239 | 2,208 | 2,238 | +35 | +1.6% | 19,800 |
| 2024/09/19 | 2,209 | 2,222 | 2,194 | 2,203 | +9 | +0.4% | 16,500 |
101～
150
件表示中 / 3692件
類似銘柄と比較する
現在ご覧いただいている「扶桑薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 扶桑薬 | 238,800円 | +8.3% | +98.1% | 3.43% | 7.85倍 | 0.54倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
| ミズホメディ | 150,300円 | +1.2% | -13.9% | 5.66% | 8.86倍 | 1.65倍 |
|
体外検査薬専業、感染症抗体、遺伝子検査機器、試薬開発。新型コロナで急成長、妊娠検査薬も |
| アンジェス | 7,800円 | +110.0% | - | 0.00% | - | 12.68倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
| ＣＡＮＢＡＳ | 103,600円 | - | - | 0.00% | - | 6.63倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
| ステムリム | 31,700円 | - | - | 0.00% | - | 2.92倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
市場注目の銘柄
チャート関連のコラム
